The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion

Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: ASRM@asrm.org; Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology

doi:10.1016/j.fertnstert.2018.01.002

The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion

Fertil Steril. 2018 Mar;109(3):429-436. doi: 10.1016/j.fertnstert.2018.01.002.

Authors

Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: [email protected]¹; Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology

Affiliation

¹ American Society for Reproductive Medicine, Birmingham, Alabama.

PMID: 29566854
DOI: 10.1016/j.fertnstert.2018.01.002

Abstract

The value of preimplantation genetic testing for aneuploidy (PGT-A) as a screening test for in vitro fertilization (IVF) patients has yet to be determined. Several studies demonstrate higher birth rates after aneuploidy testing and elective single-embryo transfer (eSET), suggesting the potential for this testing to decrease the risk of multiple gestations, though these studies have important limitations.

Publication types

Practice Guideline
Review

MeSH terms

Aneuploidy*
Consensus
Female
Fertilization in Vitro / adverse effects*
Genetic Testing / standards*
Humans
Predictive Value of Tests
Pregnancy
Pregnancy Complications / genetics
Pregnancy Outcome
Preimplantation Diagnosis / methods
Preimplantation Diagnosis / standards*
Reproductive Medicine / standards*
Risk Assessment
Risk Factors